H. Schelleken and K. Su, How similar do " biosimilars " need to be? Nature biotechnology, pp.1357-1359, 2004.

V. Brinks, A. Hawe, and A. Basmeleh, Quality of Original and Biosimilar Epoetin Products, Pharmaceutical Research, vol.95, issue.Suppl 3, pp.386-393, 2010.
DOI : 10.1007/s11095-010-0288-2

M. Weise, M. Bielsky, D. Smet, and K. , Biosimilars???why terminology matters, Nature Biotechnology, vol.18, issue.8, pp.690-693, 1936.
DOI : 10.1016/j.clinthera.2009.02.014

M. Weise, M. Bielsky, D. Smet, and K. , Biosimilars: what clinicians should know, Blood, vol.120, issue.26, pp.5111-511710, 2012.
DOI : 10.1182/blood-2012-04-425744

P. Declerck, F. Darendeliler, and M. Góth, Biosimilars: controversies as illustrated by rhGH, Current Medical Research and Opinion, vol.26, issue.5, pp.1219-1229, 2010.
DOI : 10.1185/03007991003719642

J. Bouchet, P. Brunet, and B. Canaud, Recommandations d???utilisation des biosimilaires de l?????rythropo????tine (EPO). Propositions de la Soci??t?? de n??phrologie, de la Soci??t?? francophone de dialyse et de la Soci??t?? de n??phrologie p??diatrique, N??phrologie & Th??rapeutique, vol.5, issue.1, pp.61-66, 2009.
DOI : 10.1016/j.nephro.2008.10.006

S. Singh, L. Cousens, D. Alvarez, and P. Mahajan, Determinants of immunogenic response to protein therapeutics, Biologicals, vol.40, issue.5, pp.364-368, 2012.
DOI : 10.1016/j.biologicals.2012.06.001

H. Schellekens, Biosimilar therapeutics--what do we need to consider? NDT Plus, pp.27-36, 2009.

N. Moran, Biotech innovators jump on biosimilars bandwagon, Nature Biotechnology, vol.27, issue.4, pp.297-2991, 2010.
DOI : 10.1038/nbt0412-297a

H. Ebbers, A. Mantel-teeuwisse, E. Moors, H. Schellekens, and H. Leufkens, Today's challenges in pharmacovigilance: what can we learn from epoetins? Drug Saf, pp.273-287, 2011.

A. European-medicnes, Guideline on non-clinical and clinical development of Available at, pp.1-10, 2012.

H. Schellekens, W. Hennink, and V. Brinks, The Immunogenicity of Polyethylene Glycol: Facts and Fiction, Pharmaceutical Research, vol.46, issue.2, pp.1729-173410, 2013.
DOI : 10.1007/s11095-013-1067-7

I. Knezevic, E. Griffiths, J. Wang, L. Endrenyi, and P. Lachenbruch, Biosimilars ? Global issues, national solutions Scientific considerations for assessing biosimilar products, Data Submission Considerations: Why Biotherapeutics Are Different, pp.252-255370, 2011.

R. Vijayalakshmi, K. Sabitha, and A. K. , How dissimilarly similar are biosimilars? International research journal of pharmacy, pp.12-16

J. Wang, S. Chow, and W. Jiskoot, On the Regulatory Approval Pathway of Biosimilar Products Eprex-associated pure red cell aplasia and leachates, Pharmaceuticals. Nature biotechnology, vol.524, issue.126, pp.353-368613, 2006.

A. European-medicines, Guideline on non-clinical and clinical development of biosimilars of insulin, pp.1-10

A. European-medicines, Guideline on Similar Biological Medicinal Products, 2005.

D. Owens, W. Landgraf, A. Schmidt, R. Bretzel, and M. Kuhlmann, The Emergence of Biosimilar Insulin Preparations?A Cause for Concern? Diabetes Technology & Therapeutics, EMEA. QUESTIONS AND ANSWERS ON RECOMMENDATION FOR REFUSAL OF MARKETING APPLICATION for ALPHEON, vol.14, issue.11, pp.989-9961, 2006.

. Camus, Rapport 2012 sur les médicaments génériques, pp.1-167

R. Sarah and I. Antonio, Shaping the biosimilars opportunity Building a wall against biosimilars, IMS Health, vol.201231, issue.354, pp.1-12264, 2013.

H. Luc, Freins et leviers à l'adoption des médicamentsbiosimilaires en belgique -SYNTHÈSE, pp.1-36

N. Holtz, The follow-on biologics market: Enter at your own risk, pp.1-18, 2011.

M. Farfan-portet, S. Gerkens, I. Lepage-nefkens, I. Vinck, and F. Hulstaert, Are biosimilars the next tool to guarantee cost-containment for pharmaceutical expenditures?, The European Journal of Health Economics, vol.13, issue.5, pp.223-228, 2013.
DOI : 10.1007/s10198-013-0538-4

H. Grabowski, D. Ridley, and K. Schulman, Entry and competition in generic biologics, Managerial and Decision Economics, vol.42, issue.4-5, pp.439-451, 2007.
DOI : 10.1002/mde.1352

D. Center, . Evaluation, and . Research, Postmarket Drug Safety Information for Patients and Providers -Generic Enoxaparin Questions and Answers

B. Kaffenberger and T. Bekaii-saab, Recurrent Life-Threatening Deep Tissue Hematomas After Switching to Generic Enoxaparin: A Report and Perspective on the Approval Process for Biological Compounds, Clinical and Applied Thrombosis/Hemostasis, vol.59, issue.1, pp.104-106, 2012.
DOI : 10.1177/1076029611416641

P. Minghetti, F. Cilurzo, S. Franzé, U. Musazzi, and M. Itri, Low molecular weight heparins copies: are they considered to be generics or biosimilars? Drug Discovery Today, pp.5-6305, 2013.

L. Drouet, Low molecular weight heparin biosimilars: how much similarity for how much clinical benefit?, Targeted Oncology, vol.58, issue.8, pp.35-42, 2012.
DOI : 10.1007/s11523-011-0194-5

J. Fareed, D. Hoppensteadt, C. Schultz, Q. Ma, F. Kujawski et al., Biochemical and Pharmacologic Heterogeneity in Low Molecular Weight Heparins. Impact on the Therapeutic Profile, Current Pharmaceutical Design, vol.10, issue.9, pp.983-999, 2004.
DOI : 10.2174/1381612043452811

F. Ofosu, The United States Food and Drugs Administration Approves a Generic Enoxaparin, Clinical and Applied Thrombosis/Hemostasis, vol.3590, issue.7, pp.5-8, 2011.
DOI : 10.1177/1076029610389028

W. Jeske, E. Litinas, H. Khan, D. Hoppensteadt, and J. Fareed, A Comparison of the Pharmacodynamic Behavior of Branded and Biosimilar Enoxaparin in Primates, Clinical and Applied Thrombosis/Hemostasis, vol.23, issue.6, pp.294-298, 2012.
DOI : 10.1177/1076029611432138

F. Ofosu, A review of the two major regulatory pathways for non-proprietary low-molecular-weight heparins, Thrombosis and Haemostasis, vol.107, issue.2, pp.201-214, 2012.
DOI : 10.1160/TH11-06-0409

M. Gomes, E. Ramacciotti, and D. Hoppensteadt, An Open Label, Nonrandomized , Prospective Clinical Trial Evaluating the Immunogenicity of Branded Enoxaparin Versus Biosimilars in Healthy Volunteers Clinical and Applied Thrombosis Health Insurance Coverage of the Total Population | The Henry J. Kaiser Family Foundation. kfforg. Available at, Hemostasis, vol.17, issue.1, pp.66-69, 2011.

K. Chua, Overview of the U.S. Health Care System, 2006.

A. Bourgoin and B. Nuskey, White paper: an outlook on U.S. biosimilar competition Another nail in the biosimilar coffin? accepts biosimilar filgrastim application, Home - GaBI online -Generics and Biosimilars Initiative. gabionlinenet. Available at, pp.399-410198, 2012.

S. Kozlowski, J. Woodcock, K. Midthun, and R. Behrman, Developing the Nation's Biosimilars Program, New England Journal of Medicine, vol.365, issue.5, pp.385-388, 2011.
DOI : 10.1056/NEJMp1107285

U. Government, Patient Protection and Affordable Care Act, pp.1-906

S. Gorman, A. Pishko, J. Iwanicki, and J. Stone-hulslander, Review of Intellectual Property Law 2012-2013 Biosimilars Act: The United States' Entry into Regulating Biosimilars and Its Implications, The. Marshall J, ed. heinonlineorg. Available at: http://heinonline.org/HOL/LandingPage?handle=hein.journals/johnmars12&di v=15&id=&page=, 2014.

C. Holloway, J. Mueller-berghaus, and B. Lima, Scientific considerations for complex drugs in light of established and emerging regulatory guidance, Annals of the New York Academy of Sciences, vol.58, issue.1, pp.26-36, 2012.
DOI : 10.1111/j.1749-6632.2012.06811.x

A. Pollack, . Biotech, and . Firms, Billions at Risk, Lobby States to Limit Generics - NYTimes.com. The New York Times FDA Readies New Guidance and User Fee Program for Biosimilars, pp.1-2, 2013.

H. Ebbers, P. Chamberlain, and . Interchangeability, An insurmountable fifth hurdle? GaBI Journal, pp.88-93, 2014.

L. Endrenyi, C. Chang, S. Chow, and L. Tothfalusi, On the interchangeability of biologic drug products, Statistics in Medicine, vol.9, issue.4, pp.434-441, 2012.
DOI : 10.1002/sim.5569

. Inde and . Tresoreconomiegouvfr, Available at: http://www.tresor.economie.gouv.fr/Pays/inde Muranyi-Scheutz A. India's Healthcare System, Accessed October, vol.19, issue.2013, pp.1-48, 2014.

R. Gabble and J. Kohler, ???To patent or not to patent? the case of Novartis??? cancer drug Glivec in India???, Globalization and Health, vol.10, issue.1, pp.1-6, 2014.
DOI : 10.1016/S0140-6736(12)61513-X

K. Jayaraman, India flouts patent for blockbuster biologic, Nature Biotechnology, vol.31, issue.1, pp.9-9, 2013.
DOI : 10.1038/nbt0113-9

H. Malhotra, Biosimilars and non-innovator biotherapeutics in India: An overview of the current situation, Biologicals, vol.39, issue.5, pp.321-324, 2011.
DOI : 10.1016/j.biologicals.2011.06.018

D. India, Leadership in affordable therapeutic products: a biopharma strategy for India 2020 Emerging trend in biosimilars in India -Deloitte, pp.1-50, 2010.

B. Analytics, An Introduction to the Indian Pharmaceutical Industry, pp.1-39, 2007.

K. Jayaraman, India's Cipla sets sights on Avastin, Herceptin and EnbrelIN brief, pp.883-884, 2010.

C. M. Biosimilars, Available at: http://www.lifescienceleader.com/magazine/current-issue-3/item/4545- biosimilars-in-emerging-markets, pp.1-52, 2013.

P. Babu, An Indian manufacturer???s perspective for harmonization of guidelines for similar biotherapeutic products, Health System Financing Profile by country, pp.300-303, 2011.
DOI : 10.1016/j.biologicals.2011.06.022

A. Basso, . De-sá, . Patrícia, and M. Pelegrini, Biopharmaceutical and Biosimilar Products in Brazil: From Political To Biotechnological Overview, Journal of Bioequivalence & Bioavailability, vol.05, issue.01, pp.1-7, 2013.
DOI : 10.4172/jbb.1000135

C. Blatt, N. Bernardo, and J. Rosa, An Estimate of the Cost of Hepatitis C Treatment for the Brazilian Health System, Value in Health Regional Issues, vol.1, issue.2, pp.129-135, 2012.
DOI : 10.1016/j.vhri.2012.10.001

L. Castanheira, D. Barbano, and N. Rech, Current development in regulation of similar biotherapeutic products in Brazil, Biologicals, vol.39, issue.5, pp.308-311, 2011.
DOI : 10.1016/j.biologicals.2011.06.021

V. Azevedo, Biosimilars require scientifically reliable comparative clinical data, Revista Brasileira de Reumatologia (English Edition), vol.53, issue.1, pp.129-131, 2013.
DOI : 10.1016/S2255-5021(13)70013-0

Y. Li and L. Tian, Biosimilars: current status and countermeasures, Asian Journal of Social Pharmacy, vol.9, pp.60-63, 2014.

S. Tang, H. Brixi, and H. Bekedam, Advancing universal coverage of healthcare in China: translating political will into policy and practice, The International Journal of Health Planning and Management, vol.5, issue.5, pp.10-1002
DOI : 10.1002/hpm.2207

C. Ljungwall, China's Healthcare System, pp.1-40

J. Greenwood and C. Biotech-in, Biosimilars: Asian Markets, pp.1-2

Q. Tan, Q. Guo, and C. Fang, Characterization and comparison of commercially available TNF receptor 2-Fc fusion protein products, mAbs, vol.14, issue.6, pp.761-774, 2012.
DOI : 10.1038/nrd3746

C. Liang and J. Wang, China???s perspective on similar biotherapeutic products, Biologicals, vol.39, issue.5, pp.312-3161, 2011.
DOI : 10.1016/j.biologicals.2011.06.020

. Corée-du-sud and . Tresoreconomiegouvfr, Available at: http://www.tresor.economie.gouv.fr/Pays/coree-du-sud, 2014.

S. Joo, The South Korean Health care System. community IM Available at: https://www.med.or.jp, pp.206-209, 2009.

H. Jeong, Korea's National Health Insurance--Lessons From The Past Three Decades, Health Affairs, vol.30, issue.1, pp.136-144, 2011.
DOI : 10.1377/hlthaff.2008.0816

C. Bae, S. Kim, J. Lee, and S. Lee, Republic of Korea Available at: http://www.euro.who.int/__data, Health Systems in Transition, vol.11, pp.1-184, 2013.

M. Baik, Report South KoreaBio Technology Industry in, pp.1-12, 2011.

S. Suh and Y. Park, Regulatory guideline for biosimilar products in Korea, Biologicals, vol.39, issue.5, pp.336-3381, 2009.
DOI : 10.1016/j.biologicals.2011.06.008

B. Magdalena, Inflectra acceptation EMA (infliximab), pp.1-3

J. Lim, H. Kubavat, . De, . Et, and . Criminelles, An eye towards the biobetter in South Korea, pp.1-127

M. Lindquist and . Vigibase, the WHO Global ICSR Database System: Basic Facts, Drug Information Journal, vol.42, pp.409-419, 2007.

H. Ebbers, M. Michael, and H. Schellekens, The safety of switching beteween therapeutic proteins. Expert opinion biology therapeutic, pp.1473-1485, 2012.

H. Ebbers, T. Pieters, H. Leufkens, and H. Schellekens, Effective pharmaceutical regulation needs alignment with doctors, Drug Discovery Today, vol.17, issue.3-4, 2012.
DOI : 10.1016/j.drudis.2011.09.018